Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
出版年份 2018 全文链接
标题
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
作者
关键词
-
出版物
Frontiers in Immunology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-01-17
DOI
10.3389/fimmu.2017.01936
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma
- (2017) Andrea Ferrario et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular genetics and targeted therapy of WNT-related human diseases (Review)
- (2017) Masuko Katoh et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- (2017) Kurt Schönfeld et al. Journal of Hematology & Oncology
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
- (2017) Manoj K. Kashyap et al. Journal of Hematology & Oncology
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types
- (2017) Athanasios Kotsakis et al. LANCET ONCOLOGY
- Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
- (2017) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
- (2017) E C Pietsch et al. Blood Cancer Journal
- Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
- (2017) Reed Friend et al. Drug Design Development and Therapy
- Targeting CD157 in AML using a novel, Fc-engineered antibody construct
- (2017) Christina Krupka et al. Oncotarget
- GRP78 at the Centre of the Stage in Cancer and Neuroprotection
- (2017) Caty Casas Frontiers in Neuroscience
- Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
- (2017) Jeff Kamta et al. Frontiers in Oncology
- Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies
- (2017) Leili Aghebati-Maleki et al. SLAS Discovery
- The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells
- (2017) Patricia Macanas-Pirard et al. PLoS One
- Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
- (2017) Yanyan Zhang et al. Scientific Reports
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
- (2016) Noopur S. Raje et al. BRITISH JOURNAL OF HAEMATOLOGY
- Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia
- (2016) Tadeusz Robak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
- (2016) N. S. Raje et al. CLINICAL CANCER RESEARCH
- A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
- (2016) L. Rasche et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2016) Ranjana H. Advani et al. CLINICAL CANCER RESEARCH
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
- (2016) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- (2016) David Rizzieri CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
- (2016) Michele Dal Bo et al. CURRENT CANCER DRUG TARGETS
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
- (2016) J Yu et al. LEUKEMIA
- EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
- (2016) S Charmsaz et al. LEUKEMIA
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
- (2016) Ronan T. Swords et al. LEUKEMIA RESEARCH
- A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
- (2016) M. Broussas et al. MOLECULAR CANCER THERAPEUTICS
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
- (2016) Sheng-Bin Peng et al. PLoS One
- Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
- (2016) Norbert Vey et al. Oncotarget
- A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
- (2016) Neil E. Kay et al. Oncotarget
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
- (2016) Liesbeth Bieghs et al. Oncotarget
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
- (2016) Nestor A Molfino et al. BMJ Open
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- Monoclonal antibodies in acute lymphoblastic leukemia
- (2015) E. Jabbour et al. BLOOD
- CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance
- (2015) Lauren A. Pitt et al. CANCER CELL
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
- (2015) Taofeek Kunle Owonikoko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia
- (2015) Carlos Cuesta-Mateos et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
- (2015) Michael Y. Choi et al. Clinical Lymphoma Myeloma & Leukemia
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Antitumor activity of an anti-CD98 antibody
- (2015) Gregory M. Hayes et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Genetic factors influencing the risk of multiple myeloma bone disease
- (2015) D C Johnson et al. LEUKEMIA
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
- (2015) Luis Fayad et al. LEUKEMIA & LYMPHOMA
- Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys
- (2015) S Dudal et al. mAbs
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
- (2015) D. S. Pereira et al. MOLECULAR CANCER THERAPEUTICS
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
- (2015) John E. Janik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
- (2015) Katherine Rybinski et al. Oncotarget
- Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
- (2015) Manoj K. Kashyap et al. Oncotarget
- CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation
- (2015) Aldo M. Roccaro et al. Cell Reports
- Targeted Therapies in Adult B-Cell Malignancies
- (2015) Jean-François Rossi Biomed Research International
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
- (2015) L. Rasche et al. HAEMATOLOGICA
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Tetraspanins as therapeutic targets in hematological malignancy: a concise review
- (2015) Kyle A. Beckwith et al. Frontiers in Physiology
- The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia
- (2015) Julia Christine Gutjahr et al. Frontiers in Immunology
- Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
- (2015) Maria Vela et al. Frontiers in Immunology
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
- (2015) Paul J Neeson et al. OncoImmunology
- Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
- (2015) De-Kuan Chang et al. OncoImmunology
- A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies
- (2015) Hélène Sicard et al. OncoImmunology
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Chemokines in tumor progression and metastasis
- (2015) Purvaba J. Sarvaiya et al. Oncotarget
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
- (2014) J. C. Byrd et al. BLOOD
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
- (2014) J. A. Woyach et al. BLOOD
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Immunotoxins for leukemia
- (2014) A. S. Wayne et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF- B mediates chemoresistance
- (2014) R. Jacamo et al. BLOOD
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™therapeutic protein, for relapsed or refractory NHL patients
- (2014) John M. Pagel et al. BRITISH JOURNAL OF HAEMATOLOGY
- IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma
- (2014) A. Marie-Cardine et al. CANCER RESEARCH
- Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
- (2014) T. Kanazawa et al. CLINICAL CANCER RESEARCH
- Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
- (2014) X. Ni et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
- (2014) L. A. Diaz et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
- (2014) R. A. Previs et al. CLINICAL CANCER RESEARCH
- Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma
- (2014) Jonathan L. Berkowitz et al. CLINICAL IMMUNOLOGY
- Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma
- (2014) John D. Hainsworth et al. Clinical Lymphoma Myeloma & Leukemia
- Elotuzumab for the treatment of multiple myeloma
- (2014) Philippe Moreau et al. Future Oncology
- CCR4 and its ligands: from bench to bedside
- (2014) O. Yoshie et al. INTERNATIONAL IMMUNOLOGY
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- Denosumab for Treatment of Hypercalcemia of Malignancy
- (2014) Mimi I. Hu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
- (2014) Luis-Alberto Pérez-Quintero et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
- (2014) A. Kretz-Rommel et al. JOURNAL OF IMMUNOLOGY
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
- (2014) K A Beckwith et al. LEUKEMIA
- IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors
- (2014) M Jourdan et al. LEUKEMIA
- A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
- (2014) Simon Z. He et al. LEUKEMIA & LYMPHOMA
- Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts
- (2014) Sonia Chamorro et al. mAbs
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
- (2014) Ada H. V. Repetto-Llamazares et al. PLoS One
- Potential role of daratumumab in the treatment of multiple myeloma
- (2014) Tomer Mark et al. OncoTargets and Therapy
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Effects of RANKL-Targeted Therapy in Immunity and Cancer
- (2014) Michael L. Cheng et al. Frontiers in Oncology
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
- (2013) E. Padron et al. BLOOD
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia
- (2013) N. Yaktapour et al. BLOOD
- The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
- (2013) J. Hoellenriegel et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy
- (2013) Y.-T. Hsieh et al. BLOOD
- In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma
- (2013) Samantha Pozzi et al. BONE
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
- (2013) Kouichirou Aida et al. CANCER SCIENCE
- Monoclonal antibodies in treatment of multiple sclerosis
- (2013) P. S. Rommer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results
- (2013) Jia Ruan et al. Clinical Lymphoma Myeloma & Leukemia
- The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity
- (2013) Fabien B. Vincent et al. CYTOKINE & GROWTH FACTOR REVIEWS
- CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
- (2013) Ye Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
- (2013) Beatriz Somovilla-Crespo et al. Journal of Hematology & Oncology
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
- (2013) D Atanackovic et al. LEUKEMIA
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies
- (2013) Sarwish Rafiq et al. mAbs
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- Granulocyte–macrophage colony-stimulating factor: not just another haematopoietic growth factor
- (2013) Alejandro Francisco-Cruz et al. MEDICAL ONCOLOGY
- Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML
- (2013) E. A. R. Sison et al. MOLECULAR CANCER RESEARCH
- The Natural Human IgM Antibody PAT-SM6 Induces Apoptosis in Primary Human Multiple Myeloma Cells by Targeting Heat Shock Protein GRP78
- (2013) Leo Rasche et al. PLoS One
- Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44
- (2013) S. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- VEGF isoforms
- (2013) Martine Perrot-Applanat Cell Adhesion & Migration
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies
- (2012) Ira V. Gupta et al. Annals of the New York Academy of Sciences
- A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
- (2012) A. T. Stopeck et al. BLOOD
- Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
- (2012) G. J. Ossenkoppele et al. BLOOD
- How I treat prolymphocytic leukemia
- (2012) C. Dearden BLOOD
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
- (2012) Rosa Lapalombella et al. CANCER CELL
- Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study
- (2012) Carmen D. Schweighofer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
- (2012) B. J. Schmiedel et al. CANCER RESEARCH
- Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
- (2012) Ivetta Danylesko et al. Clinical & Developmental Immunology
- BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
- (2012) M. R. Kuhne et al. CLINICAL CANCER RESEARCH
- Obinutuzumab for the treatment of lymphoproliferative disorders
- (2012) Carolyn Owen et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD98 at the crossroads of adaptive immunity and cancer
- (2012) J. M. Cantor et al. JOURNAL OF CELL SCIENCE
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Crosstalk between Human IgG Isotypes and Murine Effector Cells
- (2012) M. B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
- (2012) D.-K. Chang et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma
- (2012) Thomas Han et al. PLoS One
- The pros and cons of chemokines in tumor immunology
- (2012) Antonella Viola et al. TRENDS IN IMMUNOLOGY
- EPHA3 as a novel therapeutic target in the hematological malignancies
- (2012) Niamh Keane et al. Expert Review of Hematology
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas
- (2012) Kensei Tobinai et al. Current Hematologic Malignancy Reports
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
- (2011) M. P. Chao et al. BLOOD
- Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas
- (2011) M. Guadagnoli et al. BLOOD
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
- (2011) Klaus Podar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
- (2011) T. S. Lewis et al. CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
- (2011) D. G. Duda et al. CLINICAL CANCER RESEARCH
- Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma
- (2011) D. Vishwamitra et al. HAEMATOLOGICA
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice
- (2011) C I-U Chen et al. LEUKEMIA
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
- (2011) J. A. Burger Hematology-American Society of Hematology Education Program
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
- (2010) J. Moreaux et al. BLOOD
- Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia
- (2010) J. Wang et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- (2010) Kensei Tobinai et al. CANCER SCIENCE
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
- (2010) T. Ishii et al. CLINICAL CANCER RESEARCH
- CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
- (2010) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
- (2010) Lene Meldgaard Knudsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Galiximab: a review
- (2010) Seema Bhat et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
- (2010) Tait Shanafelt et al. LEUKEMIA & LYMPHOMA
- Monoclonal antibody therapy in multiple sclerosis
- (2010) Paulo Fontoura mAbs
- Therapeutic antibody targeting of individual Notch receptors
- (2010) Yan Wu et al. NATURE
- Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma
- (2010) L. POUR et al. NEOPLASMA
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors
- (2010) Miguel Aste-Amézaga et al. PLoS One
- Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
- (2010) J. D. Shields et al. SCIENCE
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection
- (2009) Markus Moll et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
- (2009) N. Chapuis et al. HAEMATOLOGICA
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses
- (2009) Eduardo J Villablanca et al. NATURE MEDICINE
- Glycosylation as a strategy to improve antibody-based therapeutics
- (2009) Roy Jefferis NATURE REVIEWS DRUG DISCOVERY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
- (2008) M. Luqman et al. BLOOD
- CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
- (2008) A. W. Ho et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
- (2008) E. Belnoue et al. BLOOD
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- Anti-CD20 monoclonal antibody therapy in multiple myeloma
- (2008) Prashant Kapoor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms
- (2008) Kyoichi Kaira et al. CANCER SCIENCE
- Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Baskar et al. CLINICAL CANCER RESEARCH
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
- (2008) J. A. McEarchern et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia
- (2008) D. Rossi et al. HAEMATOLOGICA
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*
- (2008) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now